^(64)Cu标记生长抑素受体显像剂的研究进展  

Progress in Researches on ^(64)Cu-labeled Somatostatin Receptors Imaging Agents

作　　者：谭思婷 尹吉林[1] 王欣璐[1] 张金赫[1] 周崝[1] 王成[1] 

机构地区：[1]广州军区广州总医院核医学科PET/CT中心

出　　处：《中国医学计算机成像杂志》2015年第4期398-403,共6页Chinese Computed Medical Imaging

基　　金：广东省自然科学基金(No.S2012010010685;No.S2013040016926);广东省教育部产学研结合项目(No.2012B091100172)~~

摘　　要：生长抑素受体在大多数神经内分泌肿瘤细胞表面过表达,可作为很好的靶点用于放射性显像及治疗研究。由于具有良好的核物理性质和生物半衰期,近年来^(64)Cu标记的生长抑素受体显像剂成为神经内分泌肿瘤重要的诊断和治疗工具。在这些靶向肿瘤分子研究中,新型稳定的双功能螯合剂(BFC)起至关重要的作用,同时,非螯合的纳米技术标记方法也成为^(64)Cu标记生物分子的新兴发展趋势。本文对^(64)Cu标记生长抑素受体显像剂的研究发展作一综述。Somatostatin receptors are overexpressed in a wide range of neuroendocrine tumors, making them excellent targets for nuclear imaging and therapy. With its superior physical properties and biological half-life, 64Cu-labeled somatostatin receptors radiopharmaceuticals become an importantly diagnostic and therapeutic tool in positron emission tomograpby in recent years. Newly stable bifunctional chelators act as an important role in the researching of the somatostatin receptors targeting tumor molecules. Meanwhile, nanotechnology of non-chelated labeling method is becoming a new trend of 64Cu-labeling biological molecules development. This review emphasizes developments of 64Cu-labeled somatostatin receptors imaging agents in the past.

关 键 词：64Cu 生长抑素受体显像剂 螯合剂 神经内分泌肿瘤 

分 类 号：R730.44[医药卫生—肿瘤]